

CRB HEALTH TECH VENTURE CAPITAL FIRM

Founded in 2010, CRB Health Tech (formerly CRB Inverbío) is one of the first Venture Capital firms specialised in technology-based projects in the field of medicine and life sciences in Spain.

Registered in the National Securities Market Commission (CNMV) under number 87, CRB Health Tech and its team of seven, highly experienced professionals in the health-care sector, currently manages three funds: CRB SCR, a seed health fund, CRB BIO II FCR, an early-stage Venture Capital fund, and Nuubo FCRE, all focusing on biotech and medtech. CRB is currently launching its fourth fund focused on Digital Health.

The total committed capital in the three aforementioned vehicles, exceeds €50M and the resulting portfolio includes diagnostics, med tech, and digital health companies, most of them with value propositions already in the commercial stage, free of technological or regulatory risk.

CRB Health Tech provides not only capital to its participated companies, but takes an active role in value creation, according to the specific needs of each of them.

Some companies participated for CRB Health Tech are: **Biocross**, **Venter Pharma**, **Amadix**, **Nuubo**, **Mecwins**, **Aglaris**, and many others.

You can find all additional info at:
www.crbinverbio.com

MANAGING PARTNERS

Enrique Castellón

MD Internal Medicine, BA Economics, MPH MSc Health Policy Harvard University, Former Chairman and Founder of the Spanish Drug Agency, National Institute for Cancer Research (CNIO) and National Institute for Cardiovascular Diseases (CNIC). Deputy Minister for Health and Social Services in Madrid. General Director of the Galician Health Services.



Manuel Castellón

Lawyer and Economist. Master in Legal Counseling. 25 years of experience as corporate lawyer. Director and certified company counsel in various media companies. Founder of Castellón Abogados.



Joaquín Velasco

Former EY Partner, BA in Economic Sciences by the Universidad Complutense de Madrid and Audit Juror Censor. He joined Ernst & Young in 1979 and his last position was Managing Director of Fiscal and Legal for the countries of the south of Europe.



1 of the **FIRST**
Venture
Capital Firms
specialised in Tech
in Medicine &
Life Sciences
in Spain

Expected
Return to obtain an
IRR of +40%
a multiple of **x5** times
the investment
that was made

LAUNCHING
4th Fund
SOON

FOUNDED IN
2010

CURRENTLY
3 Funds
MANAGED

TOTAL
COMMITTED CAPITAL
+€50M
DIAGNOSTICS, MED TECH
& DIGITAL HEALTH
COMPANIES

MOST VALUE
PROPOSITIONS
ALREADY IN THE
PORTFOLIO

At commercial stage,
free of technological or
regulatory risk

Biocross:
€6M
TOTAL RAISED
till now

INVESTMENT OPPORTUNITY

To invest in Biocross innovative products, via CRB Token Health I, a blockchain company. **Biocross portfolio is almost free of technological or regulatory risk [TRL7&8] and is approved for the European market** in the areas of prognosis/risk of prevalent diseases.

In the near future, its products e4Risk[TRL8] and e4Quant [TRL7], will add real clinical diagnostic advantages to the ApoE4-related pathologies, such as Alzheimer's disease, cardiovascular diseases, and type II diabetes mellitus. The portfolio is protected by robust intellectual property filing. To date, the total amount raised by the company is six million euros.

Disinvestment and profitability:

The company foresees an exit/disinvestment over the next four years. The expected return, if the forecasts that support the Business Case are met, is to obtain an IRR of over 40% and a multiple of x5 times the investment made.